US20030018176A1 - Dry acid-chitosan complexes - Google Patents
Dry acid-chitosan complexes Download PDFInfo
- Publication number
- US20030018176A1 US20030018176A1 US09/947,248 US94724801A US2003018176A1 US 20030018176 A1 US20030018176 A1 US 20030018176A1 US 94724801 A US94724801 A US 94724801A US 2003018176 A1 US2003018176 A1 US 2003018176A1
- Authority
- US
- United States
- Prior art keywords
- acid
- chitosan
- complex
- water
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 179
- 239000002253 acid Substances 0.000 claims abstract description 89
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 33
- 241001465754 Metazoa Species 0.000 claims abstract description 26
- 150000007513 acids Chemical class 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 claims description 19
- 229960003403 betaine hydrochloride Drugs 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 7
- -1 amine hydrochlorides Chemical class 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 150000001735 carboxylic acids Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims 43
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 15
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 10
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 10
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 5
- 239000004310 lactic acid Substances 0.000 claims 5
- 235000014655 lactic acid Nutrition 0.000 claims 5
- 239000001630 malic acid Substances 0.000 claims 5
- 235000011090 malic acid Nutrition 0.000 claims 5
- 229910017604 nitric acid Inorganic materials 0.000 claims 5
- 229940107700 pyruvic acid Drugs 0.000 claims 5
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000003925 fat Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 230000005588 protonation Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 230000003082 hepatotoxic effect Effects 0.000 description 2
- 235000015263 low fat diet Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 229940002552 xenical Drugs 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000002464 physical blending Methods 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
Definitions
- the present invention relates to essentially dry complexes of acid and chitosan which are water-soluble. More specifically, the invention relates to water-soluble acid-chitosan complexes, methods for forming such complexes and uses of these acid-chitosan complexes for, among other things, prevention of fat digestion.
- chitosan When chitosan is prepared from the chitin fraction of the shells of crustcea, such as shrimp, crab and lobster, the final step is invariably and of necessity a treatment with extremely strong sodium hydroxide. This is the predominant industrial treatment that effectively removes acetyl groups from chitin, converting it into chitosan. Because of this treatment, chitosan is always found as an aminopolysaccharide with essentially none of the amino groups being protonated. This can be referred to as the free base form of chitosan. This natural form of chitosan is not soluble in water. In order to dissolve chitosan in water-based systems, the chitosan must be made more hydrophilic.
- Chitosan is presently used as a dietary supplement to prevent some of the ingested fat in a person's diet from being absorbed and metabolized. It is thus an agent to help control obesity.
- the chitosan exerts a demand on the stomach to produce hydrochloric acid in order to dissolve it. It is understood in the art that the chitosan must dissolve to be able to occlude the fat, which can thereafter be passed through the digestive tract and subsequently expelled from the body. Since the body's capacity for producing hydrochloric acid is limited, an agent that supplies part of the necessary acidity would be beneficial to chitosan's performance.
- water-soluble chitosans are prepared by making a slurry of the chitosan in water and then adding acid to the slurry. Alternatively, one may make a solution of the acid and water and then add the chitosan under effective agitation conditions. It would be convenient, however, and represent an advance in the art, were all or part of the acid to be compounded with the chitosan thus providing a uniform dry complex which can be a shelf-stable product that will result in a reduced demand on the stomach for acid.
- a more soluble acid, a higher amount of acid and/or the use of higher levels of water will result in a complex that is nearer to the fully-protonated extreme, whereas the use of a less soluble acid, lesser amounts of acid and/or lesser amounts of water will result in a complex that is much less protonated.
- acid-chitosan mixture means the physical blend of dry acid and chitosan wherein no protonation of any significance of the chitosan occurs.
- acid-chitosan complex means the mixture of acid and chitosan with the addition of controlled amounts of water to form a uniform, free-flowing mix such that the acid molecules attain the necessary mobility to accomplish at least partial protonation of the chitosan, to allow the acid-chitosan combination to become water-soluble.
- finished moisture level means the weight percent of water in an acid-chitosan complex, based on the total weight of the complex, following the agitation step and before any optional or necessary drying of the complex is performed.
- a water-soluble acid-chitosan complex may be easily and effectively produced by adding varying amounts of one or more acids and a modest amount of water to a sufficiently-agitated chitosan powder or flake, mixing to achieve uniformity and, if necessary, drying the resulted hydrated crumb.
- a water-soluble acid-chitosan complexes may be prepared that range from completely water-soluble to hydratable and soluble by the addition of lesser quantities of acid than with native chitosan.
- the technique and amount of water and acid addition are important to the successful practice of the present technology.
- Water is added as a carrier for the acid, allowing it to dissolve, ionize and penetrate the chitosan particle, and carry out at least partial protonation, thereby producing a complex of at least partial salt formation between the acid and the chitosan. If too little water is added, the acid molecules will not be sufficiently mobile to penetrate the particle and give a uniform product. If too much water is added, the hydrated chitosan will begin to approach a solution; this is not desired because large, hydrated gel masses may form and the product becomes very difficult to process through the necessary (in that case) drying and grinding operations required to produce a finished, marketable product.
- the amount of water used be in the range of approximately 5% to 130% of the total weight of the chitosan and the acid, and more preferable that the amount of water added be in the range of 5% to 15%.
- the acid to be used must be sufficiently water soluble to at least partially dissolve in the water used. In the case of less soluble acids, longer mix times may be necessary to give a more uniform product. This is generally necessary to form the water-soluble acid-chitosan complex, otherwise a true complex will not be formed, and instead, a partial complex and what is essentially a non-homogeneous mixture of acid and chitosan will form.
- the acid is a liquid, it is preferred that it be dissolved in the process water and thereafter sprayed onto the chitosan. If the acid is a solid, it may either be dry-blended or, if it is sufficiently water soluble, it may be dissolved in the water and the solution sprayed onto the chitosan powder or flake. Because a major necessity of the process is the diffusion of the acid, mediated by the water, into the chitosan solid, it may be easily seen that a period of mixing of the acid with the chitosan subsequent to the introduction of water to the chitosan is necessary to assure a homogeneous product.
- the acids that are operative in the process preferably include, but are not limited to, hydrochloric, acetic, lactic, glycolic, nitric, malic, pyruvic, citric, ascorbic, and other physiologically acceptable carboxylic acids.
- Other acidic substances such as betaine hydrochloride or amine hydrochlorides, such as glycine hydrochloride, which are more acidic than the amino group on chitosan, are also effective.
- the crux of the invention is that the use of acid and water with the chitosan and with good agitation allows a reaction between the acid and the chitosan, resulting in the formation of a true chemical complex, rather than just an intimate blend of the two components.
- the complex can be best described as a salt of chitosan, acting as a base, with one or more acidic species (see definition above).
- a preferred embodiment is the complex of chitosan with betaine hydrochloride.
- the applicants have found that a dry blend of 100 parts of chitosan and 75 parts of betaine hydrochloride, when treated with water according to the invention to form a complex, forms a homogeneous, water soluble solid. Conversely, when a dry blend or mixture was prepared of the two compounds in the same ratio, the two materials separated, due to their large difference in bulk density, and samples taken from different parts of the container showed greatly different solubility properties.
- the applicants have found that adding 10% water, based on the sum of the weights of chitosan and betaine hydrochloride, to a mixture of chitosan and betaine hydrochloride and mixing after the addition, gives a dry powder which easily disperses and dissolves in water to give a viscous chitosan solution.
- applicants have treated the chitosan in the manner of the invention with lesser amounts of acid to give products that disperse in water and, upon the addition of lesser than usually employed amounts of acid, form a viscous solution of chitosan.
- Another aspect of the invention relates to the use of water-soluble acid-chitosan complexes in the prevention of fat digestion and the overall improvement of an animal's health.
- a water-soluble acid-chitosan complex and in particular, that of chitosan and betaine hydrochloride, is administered to an animal prior to or during digestion of fat-containing substances, the triglyceride levels within that animal are reduced to levels significantly below those observed with the use of chitosan as known in the prior art.
- Triglyceride levels are known in the art as a measure of fat availability within an animal's system. The following pragraph sets forth a description of trigycerides.
- a triglyceride is a primary form of fat transported within an animal's body. Triglycerides are found as a normal component in an animal's bloodstream. They are compounds (esters) of fatty acids and glycerol that bind to proteins and form low-density lipoprotein (LDL) and very-low density lipoprotein (VLDL). Normally, triglyceride levels rise immediately after eating. In particular, after an animal eats, its body digests the fats from the food and then releases triglycerides into the bloodstream. The triglycerides are transported throughout the body of the animal to give the animal energy or they are easily stored as fat. Thus, as is known in the prior art, a reduction in the level of triglycerides is directly correlated to a reduction in the fat available to the body through the digestive process.
- the liver also produces triglycerides and converts some into cholesterol. Further, there is a link between triglyceride levels and the development of coronary heart disease. High triglyceride levels are an important predictor of myocardial infarction. LDL and VLDL contain large amounts of cholesterol and triglycerides that can adhere to the arteries in the form of fatty plaques. Therefore, a reduction in triglycerides has several beneficial aspects.
- the administration of the acid-chitosan complex to an animal also has a beneficial effect on the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in that animal.
- AST aspartate aminotransferase
- ALT alanine aminotransferase
- the levels of AST and/or ALT in an animal relate to characteristics of liver function. For example, ALT levels are present in kidney and muscle as well as liver, and are used to confirm that AST elevations are of liver origin.
- ALT and AST levels were generally found to be significantly lower than that in commercially available chitosan and even the positive control of the drug XenicalTM.
- Water-soluble acid-chitosan complexes are found to be less hepatotoxic than commercially available Chitosan or XenicalTM in animals being fed such products.
- chitosan from the same original lot that had been treated in the manner of the invention such as to form the acid-chitosan complex with a 10% ratio of 100% hydrochloric acid to chitosan (2 g at 1.4% moisture, representing 1.79 g of 100% chitosan) was dissolved and adjusted to pH 3.0. While the pH of the water before introduction of the chitosan was observed to be 7.30, the pH drifted down to 5.7 before any acid was added and the chitosan was observed to visibly begin to hydrate, indicating partial solubility ascribed to partial formation of the acid-chitosan complex.
- BetasanneTM chitosan and betaine hydrochloride complex prepared by any of the methods described in the above examples
- Betasanne is the closest to the high fat and low fat diet, thus showing that it is the least hepatotoxic.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Child & Adolescent Psychology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention is an acid-chitosan complex which is made up of chitosan, a sufficient amount of one or more acids, and an effective amount of water. This acid-chitosan is water-soluble in a dry form. A further aspect of this invention is various methods for producing such a water-soluble acid-chitosan complex and methods for using this acid-chitosan complex, particularly for reducing fat absorption in an animal.
Description
- This application is a continuation of U.S. application Ser. No. 09/515,051 filed Feb. 25, 2000.
- The present invention relates to essentially dry complexes of acid and chitosan which are water-soluble. More specifically, the invention relates to water-soluble acid-chitosan complexes, methods for forming such complexes and uses of these acid-chitosan complexes for, among other things, prevention of fat digestion.
- When chitosan is prepared from the chitin fraction of the shells of crustcea, such as shrimp, crab and lobster, the final step is invariably and of necessity a treatment with extremely strong sodium hydroxide. This is the predominant industrial treatment that effectively removes acetyl groups from chitin, converting it into chitosan. Because of this treatment, chitosan is always found as an aminopolysaccharide with essentially none of the amino groups being protonated. This can be referred to as the free base form of chitosan. This natural form of chitosan is not soluble in water. In order to dissolve chitosan in water-based systems, the chitosan must be made more hydrophilic. This is done by adding acid to the water being used in dissolution. The acid reacts with the amino groups, converting them into (substituted) ammonium ions, which are much more hydrophilic than the amino groups. When chitosan is added to this acid-water mix, it becomes protonated. A fully protonated (i.e., each amino group has reacted with a proton from the acid) chitosan is the other extreme of chitosan. It should be noted, however, that essentially no protonation of chitosan will result if a dry acid and chitosan are merely physically blended. It is necessary to give the acid molecule mobility, which is done by the addition of water.
- Chitosan is presently used as a dietary supplement to prevent some of the ingested fat in a person's diet from being absorbed and metabolized. It is thus an agent to help control obesity. When a person takes a dosage of chitosan, the chitosan exerts a demand on the stomach to produce hydrochloric acid in order to dissolve it. It is understood in the art that the chitosan must dissolve to be able to occlude the fat, which can thereafter be passed through the digestive tract and subsequently expelled from the body. Since the body's capacity for producing hydrochloric acid is limited, an agent that supplies part of the necessary acidity would be beneficial to chitosan's performance.
- Merely treating chitosan with hydrochloric acid in a manufacturing process to form a water-soluble chitosan, however has an unintended and devastating side effect. It has been observed that these hydrochloric acid salts of chitosan undergo depolymerization upon storage, producing a product with too low a molecular weight to perform in the desired manner.
- Presently, in the art, water-soluble chitosans are prepared by making a slurry of the chitosan in water and then adding acid to the slurry. Alternatively, one may make a solution of the acid and water and then add the chitosan under effective agitation conditions. It would be convenient, however, and represent an advance in the art, were all or part of the acid to be compounded with the chitosan thus providing a uniform dry complex which can be a shelf-stable product that will result in a reduced demand on the stomach for acid. To date, the only way to prepare such a complex has been achieved, with great difficulty, has been for the manufacturer to 1) dissolve the chitosan in aqueous acid, 2) filter the very viscous solution to remove insolubles, if necessary, and 3) spray dry the resulting solution to form a chitosan salt that is water soluble. Such a process is cumbersome, expensive and ineffective for an economically viable commercial process. Therefore, there is a need in the art for a more efficient and effective method of preparing chitosan salts.
- It is a primary object of this invention to provide a water-soluble, acid-chitosan complex.
- It is also an object of the invention to provide a water-soluble acid-chitosan complex produced by a process comprising:
- (1) forming a homogenous mix of chitosan and a sufficient amount of an acid; and
- (2) adding an effective amount of water to the homogenous mix to form a uniform complex.
- It is a further object of the invention to provide a water-soluble acid-chitosan complex produced by a process comprising:
- (1) dissolving an acid in water; and
- (2) applying the acid-water mix to chitosan to form a complex wherein the chitosan is not dissolved; and
- (3) drying the complex.
- It is an additional object of the invention to provide a method for reducing the release of triglycerides into the blood stream of an animal by administering to the animal an effective amount of a water-soluble acid-chitosan complex.
- The applicants have found that the physical blending of dry acid and chitosan, with the addition of controlled amounts of water, gives the acid molecules the needed mobility to accomplish protonation and thus move from a physical mixture to a complex (further defined below). The result of such a treatment is a state, or complex, somewhere between full-protonation and no protonation. The exact composition of the complex is dependent on the amount of water and acid used and the water solubility of the acid being used in the treatment. A more soluble acid, a higher amount of acid and/or the use of higher levels of water will result in a complex that is nearer to the fully-protonated extreme, whereas the use of a less soluble acid, lesser amounts of acid and/or lesser amounts of water will result in a complex that is much less protonated.
- Definitions:
- The following definitions apply throughout:
- The term “acid-chitosan mixture” means the physical blend of dry acid and chitosan wherein no protonation of any significance of the chitosan occurs.
- The term “acid-chitosan complex” means the mixture of acid and chitosan with the addition of controlled amounts of water to form a uniform, free-flowing mix such that the acid molecules attain the necessary mobility to accomplish at least partial protonation of the chitosan, to allow the acid-chitosan combination to become water-soluble.
- The term “finished moisture level” means the weight percent of water in an acid-chitosan complex, based on the total weight of the complex, following the agitation step and before any optional or necessary drying of the complex is performed.
- The Invention:
- It is the applicants' discovery that a water-soluble acid-chitosan complex may be easily and effectively produced by adding varying amounts of one or more acids and a modest amount of water to a sufficiently-agitated chitosan powder or flake, mixing to achieve uniformity and, if necessary, drying the resulted hydrated crumb. By this technique, one can vary the amount of acid used from a very small amount up to essentially a stoichiometric quantity, and water-soluble acid-chitosan complexes may be prepared that range from completely water-soluble to hydratable and soluble by the addition of lesser quantities of acid than with native chitosan.
- The technique and amount of water and acid addition are important to the successful practice of the present technology. Water is added as a carrier for the acid, allowing it to dissolve, ionize and penetrate the chitosan particle, and carry out at least partial protonation, thereby producing a complex of at least partial salt formation between the acid and the chitosan. If too little water is added, the acid molecules will not be sufficiently mobile to penetrate the particle and give a uniform product. If too much water is added, the hydrated chitosan will begin to approach a solution; this is not desired because large, hydrated gel masses may form and the product becomes very difficult to process through the necessary (in that case) drying and grinding operations required to produce a finished, marketable product. In this respect, it is preferred that the amount of water used be in the range of approximately 5% to 130% of the total weight of the chitosan and the acid, and more preferable that the amount of water added be in the range of 5% to 15%.
- The acid to be used must be sufficiently water soluble to at least partially dissolve in the water used. In the case of less soluble acids, longer mix times may be necessary to give a more uniform product. This is generally necessary to form the water-soluble acid-chitosan complex, otherwise a true complex will not be formed, and instead, a partial complex and what is essentially a non-homogeneous mixture of acid and chitosan will form.
- If the acid is a liquid, it is preferred that it be dissolved in the process water and thereafter sprayed onto the chitosan. If the acid is a solid, it may either be dry-blended or, if it is sufficiently water soluble, it may be dissolved in the water and the solution sprayed onto the chitosan powder or flake. Because a major necessity of the process is the diffusion of the acid, mediated by the water, into the chitosan solid, it may be easily seen that a period of mixing of the acid with the chitosan subsequent to the introduction of water to the chitosan is necessary to assure a homogeneous product.
- The acids that are operative in the process preferably include, but are not limited to, hydrochloric, acetic, lactic, glycolic, nitric, malic, pyruvic, citric, ascorbic, and other physiologically acceptable carboxylic acids. Other acidic substances, such as betaine hydrochloride or amine hydrochlorides, such as glycine hydrochloride, which are more acidic than the amino group on chitosan, are also effective.
- The crux of the invention is that the use of acid and water with the chitosan and with good agitation allows a reaction between the acid and the chitosan, resulting in the formation of a true chemical complex, rather than just an intimate blend of the two components. The complex can be best described as a salt of chitosan, acting as a base, with one or more acidic species (see definition above).
- It is applicants' discovery that mixtures of acids with chitosan, in amounts that approach or exceed stoichiometric for salt formation, provide superior performance in the fat-binding application. In a particular embodiment, acceptable betaine hydrochloride complexes with chitosan surprisingly show efficacy in the application and demonstrate good shelf stability, making them especially suitable for the application.
- Further, the applicants have found a method of preparing these chitosan salts which results in at least partial salt formation, taking the formulation from a mixture of chitosan and acid to the formation of an acid-chitosan complex. This provides for a uniform product which may be easily formulated into the final marketable product, but is still stable with regard to molecular weight of the chitosan over time.
- A preferred embodiment is the complex of chitosan with betaine hydrochloride. The applicants have found that a dry blend of 100 parts of chitosan and 75 parts of betaine hydrochloride, when treated with water according to the invention to form a complex, forms a homogeneous, water soluble solid. Conversely, when a dry blend or mixture was prepared of the two compounds in the same ratio, the two materials separated, due to their large difference in bulk density, and samples taken from different parts of the container showed greatly different solubility properties.
- The preparation of the betaine hydrochloride complex of chitosan also demonstrates the criticality of the use of controlled amounts of water. In this case, when 100 parts of chitosan were treated with 75 parts of betaine hydrochloride and 200 parts of water (which is equivalent to 115% of the total weight of the chitosan and the acid), a granular hydrated chitosan/betaine hydrochloride complex was formed, which was easily dried and ground to give product. However, when the water was increased to 250 parts (equivalent to 143% of the chitosan and the acid), the material became sufficiently hydrated and cohesive to form a stiff, gel-like mass which actually froze the blades of the Hobart mixer, causing the motor to burn out. Drying this gummy mass was quite difficult, as the gel held water for long periods of time. Upon reaching a dry state, the product formed large, extremely hard pieces of the salt, making it very difficult to grind.
- In one particular embodiment, wherein the amount of acid is sufficient to protonate enough of the amino groups of chitosan to yield a soluble product (i.e. 75% of stoichiometric or higher), the applicants have found that adding 10% water, based on the sum of the weights of chitosan and betaine hydrochloride, to a mixture of chitosan and betaine hydrochloride and mixing after the addition, gives a dry powder which easily disperses and dissolves in water to give a viscous chitosan solution.
- In an alternative embodiment, applicants have treated the chitosan in the manner of the invention with lesser amounts of acid to give products that disperse in water and, upon the addition of lesser than usually employed amounts of acid, form a viscous solution of chitosan.
- Low levels of acid generally yield chitosan complexes that are not soluble in water (i.e. not enough of the salt has been formed to render the chitosan water-soluble in its own right). This reinforces the fact that there must be an adequate number of moles of acid present to protonate a major fraction of the amine groups in the chitosan. For example, full solubilization requires at least about 0.75 moles of acid for each mole of chitosan. The acid content to be achieved will depend on how much one wants to decrease the acid demand on the stomach of an ingester of the complex.
- Another aspect of the invention relates to the use of water-soluble acid-chitosan complexes in the prevention of fat digestion and the overall improvement of an animal's health. In particular it is applicants' discovery that when an effective amount of a water-soluble acid-chitosan complex, and in particular, that of chitosan and betaine hydrochloride, is administered to an animal prior to or during digestion of fat-containing substances, the triglyceride levels within that animal are reduced to levels significantly below those observed with the use of chitosan as known in the prior art. Triglyceride levels are known in the art as a measure of fat availability within an animal's system. The following pragraph sets forth a description of trigycerides.
- A triglyceride is a primary form of fat transported within an animal's body. Triglycerides are found as a normal component in an animal's bloodstream. They are compounds (esters) of fatty acids and glycerol that bind to proteins and form low-density lipoprotein (LDL) and very-low density lipoprotein (VLDL). Normally, triglyceride levels rise immediately after eating. In particular, after an animal eats, its body digests the fats from the food and then releases triglycerides into the bloodstream. The triglycerides are transported throughout the body of the animal to give the animal energy or they are easily stored as fat. Thus, as is known in the prior art, a reduction in the level of triglycerides is directly correlated to a reduction in the fat available to the body through the digestive process.
- The liver also produces triglycerides and converts some into cholesterol. Further, there is a link between triglyceride levels and the development of coronary heart disease. High triglyceride levels are an important predictor of myocardial infarction. LDL and VLDL contain large amounts of cholesterol and triglycerides that can adhere to the arteries in the form of fatty plaques. Therefore, a reduction in triglycerides has several beneficial aspects.
- The administration of the acid-chitosan complex to an animal also has a beneficial effect on the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in that animal. The levels of AST and/or ALT in an animal relate to characteristics of liver function. For example, ALT levels are present in kidney and muscle as well as liver, and are used to confirm that AST elevations are of liver origin.
- It is Applicants' discovery that with the administration of a water-soluble acid-chitosan complex, and particularly chitosan and betaine hydrochloride, the ALT and AST levels were generally found to be significantly lower than that in commercially available chitosan and even the positive control of the drug Xenical™. Water-soluble acid-chitosan complexes are found to be less hepatotoxic than commercially available Chitosan or Xenical™ in animals being fed such products.
- The advantageous properties of this invention can be further observed by reference to the following examples which illustrate the invention.
- Sixty five grams of ground chitosan (−60 mesh), available from DCV, Inc., Wilmington, Del., was added to a Hobart mixer. Hydrochloric acid (6.5 g on a 100% acid basis) was added to enough water to make 150 ml total solution. The mixer was started at medium speed and the acid solution was sprayed onto the mix over a 5-minute period. Mixing was continued for 15 minutes following the addition of acid to yield a homogeneous, moist crumb. At that point, the moist acid-chitosan complex was put into an aluminum tray and dried overnight in a convection oven, set at 65° C. When dry, the material was re-ground to −60 mesh. The grinder used was a Tekmar grinder with cooling jacket, Model No. A-10.
- To test water solubility, a 1.5 g portion was put into a beaker with 150 g of water. A magnetic stirring bar was placed in the beaker and the solution was mixed for one hour. The solid dissolved to give a viscous solution.
- Sixty-five (65) grams of chitosan flake was added to a Waring blender. Solid betaine hydrochloride (48 g) was added to the chitosan. The mixer was started at low speed and 100 ml of water was sprayed on over a 5-minute period. Following the addition of water, the blend was mixed for an additional 10 minutes to form the homogeneous acid-chitosan complex. The moist complex was dried overnight at 55° C. and was then ground to −20 mesh using the Tekmar grinder. 2 g of this was added to water and stirred to give a viscous solution.
- Seventy five (75) pounds of chitosan was added to a Henschel mixer. Solid betaine hydrochloride (56 lbs.) was added to the chitosan. The mixer was started at low speed and 10 lbs. Of water was sprayed on over a 2 minute period. Following the addition of water, the blend was mixed for 15 minutes to form the homogenous acid-chitosan complex, which was then screened through a 20 mesh screen and packaged. Two grams of this was added to 100 ml of water. A gel was formed within 1 minute with a pH of approximately 3 with no additional acid added.
- A sample of untreated chitosan (2 g at 6.7% moisture =1.87 g chitosan on a 100% basis) was placed in 200 ml of water. The initial pH of the slurry was 7.3. One normal (1N) hydrochloric acid was added dropwise, with stirring, until a solution was formed and the final pH was 3.0. It was found that 7.75 ml of acid were required, or 4.144 meq/gm of 100% chitosan.
- In a like manner, chitosan from the same original lot that had been treated in the manner of the invention such as to form the acid-chitosan complex with a 10% ratio of 100% hydrochloric acid to chitosan (2 g at 1.4% moisture, representing 1.79 g of 100% chitosan) was dissolved and adjusted to pH 3.0. While the pH of the water before introduction of the chitosan was observed to be 7.30, the pH drifted down to 5.7 before any acid was added and the chitosan was observed to visibly begin to hydrate, indicating partial solubility ascribed to partial formation of the acid-chitosan complex. It was found that the treated sample required only 5.4 ml of acid (corresponding to 3.016 meq/gm of 100% chitosan) to lower the pH to 3.0. This is direct confirmation that partial complex formation had occurred and that there was a reduced acid demand to effect solution.
- The purpose of this study was to (1) to compare the fat binding ability of Betasanne™ (chitosan and betaine hydrochloride complex prepared by any of the methods described in the above examples) with that of various commercially available chito sans; (2) to optimize the conditions for maximum absorption of fat from the diet using Betasanne™ or commercially available chitosan; and (3) to compare the efficacy of fat binding using Betasanne™ with that of commercially available chitosan.
- Study Design
TABLE 1 Group Number of Animals Test Article 1 12 Mixture of Chitosan and 5% Vitamin C 2 12 Chitosan 3 12 Chitin 4 12 Betasanne ™ 5 12 Mixture of Chitosan and 1% Vitamin C 6 12 High Fat Diet 7 12 Xenical ™ 8 12 Low Fat Diet - All rats were fed a basal diet for 5 days prior to initiation of dosing on Day 0. At Day 0, animals in Groups 1 to 5 and 7 received the appropriate formulated diet. The diet was available ad libitum. Animals in Group 6 received only the basal diet throughout the study and animals in Group 8 received Purina Diet #5001 without the addition of additional fat throughout the study. The total amount of the diet consumed by each animal was determined every 3 to 4 days.
- Results
- Table 2 below outlines differences in weight gain and triglyceride, AST and ALT levels in the blood of the rats used in the trial as sert forth above.
TABLE 2 Chitosan + Chitosan + High Low 5% Vit C Betasanne Chitosan 1% Vit C Xenical Fat Fat Weight Gain (gms) 419 444 464 458 425 469 452 Triglycerides (mg/dL) 133 119 157 141 107 172 111 ALT (IU/L) 52 46 54 48 54 41 38 AST (IU/L) 80 63 73 64 104 67 83 Bilirubin (mg/dL) 0.4 0.3 0.5 0.5 0.4 0.6 0.2 - Conclusion and Summary
- On the basis of equal weighting for all the properties that were measured in this study, the two groups which used an acid-chitosan complex as set forth in the invention showed the greatest effects (i.e. Betasanne and Chitosan+5% ascorbic acid). The animals administered Betasanne or Chitsan+5% ascorbic gained less weight than did those animals administered either commercially available chitosan or a high fat diet. Similar results were observed for triglyceride levels.
- As for ALT and bilirubin levels, Betasanne is the closest to the high fat and low fat diet, thus showing that it is the least hepatotoxic.
Claims (27)
1. An acid-chitosan complex comprising chitosan, a sufficient amount of one or more acids, and an effective amount of water, wherein said acid-chitosan complex is water-soluble.
2. The acid-chitosan complex of claim 1 wherein the sufficient amount of acid comprises about 75% or more of stoichiometric, based on chitosan.
3. The acid-chitosan complex of claim 2 wherein the effective amount water is about 5% to 130% of the weight of the acid and the chitosan.
4. The acid-chitosan complex of claim 3 wherein the effective amount of water is about 5% to 15% of the weight of the acid and the chitosan.
5. The acid-chitosan complex of claim 1 wherein the acid is selected from the group consisting of: hydrochloric acid, acetic acid, lactic acid, glycolic acid, nitric acid, malic acid, pyruvic acid, citric acid, ascorbic acid, other physiologically acceptable carboxylic acids, betaine hydrochloride, amine hydrochlorides, and combinations thereof.
6. The acid-chitosan complex of claim 5 wherein the acid comprises betaine hydrochloride.
7. An acid-chitosan complex produced by the process comprising the following steps:
(1) forming a homogenous mix of chitosan and a sufficient amount of one or more acids; and
(2) adding an effective amount of water to the homogenous mix to form a uniform complex.
8. The acid-chitosan complex of claim 7 wherein the sufficient amount of acid comprises about 75% or more of stoichiometric, based on chitosan.
9. The acid-chitosan complex of claim 8 wherein the effective amount water is about 5% to 130% of the weight of the acid and the chitosan.
10. The acid-chitosan complex of claim 8 wherein the effective amount water is about 5% to 15% of the weight of the acid and the chitosan.
11. The acid-chitosan complex of claim 7 wherein the acid is selected from the group consisting of: hydrochloric acid, acetic acid, lactic acid, glycolic acid, nitric acid, malic acid, pyruvic acid, citric acid, ascorbic acid, other physiologically acceptable carboxylic acids, betaine hydrochloride, amine hydrochlorides, and combinations thereof.
12. An acid-chitosan complex produced by a process comprising the following steps:
(3) dissolving one or more acids in water; and
(4) applying the acid-water mix to chitosan to form a complex wherein the chitosan is not dissolved; and
(5) drying the complex.
13. The acid-chitosan complex of claim 12 wherein the sufficient amount of acid comprises about 75% or more of stoichiometric, based on chitosan.
14. The acid-chito san complex of claim 13 wherein the effective amount water is about 5% to 130% of the weight of the acid and the chitosan.
15. The acid-chitosan complex of claim 13 wherein the effective amount water is about 5% to 15% of the weight of the acid and the chitosan.
16. The acid-chitosan complex of claim 12 wherein the acid is selected from the group consisting of: hydrochloric acid, acetic acid, lactic acid, glycolic acid, nitric acid, malic acid, pyruvic acid, citric acid, ascorbic acid, other physiologically acceptable carboxylic acids and combinations thereof.
17. A method for reducing the release of trigycerides into the blood stream of an animal after the animal has digested a fat-containing substance, the method comprising administering to the animal an acid-chitosan complex prior to or during digestion of the fat-containing substance wherein the acid-chitosan complex comprises chitosan, a sufficient amount of an acid, and an effective amount of water, wherein said acid-chitosan complex is water-soluble.
18. The method of claim 17 wherein the acid-chitosan complex is produced by a process comprising the following steps:
(1) forming a homogenous mix of chitosan and a sufficient amount of one or more acids; and
(2) adding an effective amount of water to the homogenous mix to form a uniform complex.
19. The method of claim 18 wherein the sufficient amount of acid comprises about 75% of stoichiometric.
20. The method of claim 19 wherein the effective amount water is about 5% to 130% of the weight of the acid and the chitosan.
21. The method of claim 20 wherein the effective amount water is about 5% to 15% of the weight of the acid and the chitosan.
22. The method of claim 17 wherein the acid is selected from the group consisting of: hydrochloric acid, acetic acid, lactic acid, glycolic acid, nitric acid, malic acid, pyruvic acid, citric acid, ascorbic acid, other physiologically acceptable carboxylic acids, betaine hydrochloride, amine hydrochlorides, and combinations thereof.
23. The method of claim 17 wherein the acid-chitosan complex is produced by a process comprising the following steps:
(6) dissolving an acid in water; and
(7) applying the acid-water mix to chitosan to form a complex wherein the chitosan is not dissolved; and
(8) drying the complex.
24. The method of claim 23 wherein the sufficient amount of acid comprises about 75% of stoichiometric.
25. The method of claim 24 wherein the effective amount water is about 5% to 130% of the weight of the acid and the chitosan.
26. The method of claim 25 wherein the effective amount water is about 5% to 15% of the weight of the acid and the chitosan.
27. The method of claim 23 wherein the acid is selected from the group consisting of: hydrochloric acid, acetic acid, lactic acid, glycolic acid, nitric acid, malic acid, pyruvic acid, citric acid, ascorbic acid, other physiologically acceptable carboxylic acids, betaine hydrochloride, amine hydrochlorides, and combinations thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/947,248 US20030018176A1 (en) | 1999-02-25 | 2001-09-06 | Dry acid-chitosan complexes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12139199P | 1999-02-25 | 1999-02-25 | |
US09/515,051 US6326475B1 (en) | 1999-02-25 | 2000-02-25 | Dry acid-chitosan complexes |
US09/947,248 US20030018176A1 (en) | 1999-02-25 | 2001-09-06 | Dry acid-chitosan complexes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/515,051 Continuation US6326475B1 (en) | 1999-02-25 | 2000-02-25 | Dry acid-chitosan complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030018176A1 true US20030018176A1 (en) | 2003-01-23 |
Family
ID=22396413
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/515,051 Expired - Fee Related US6326475B1 (en) | 1999-02-25 | 2000-02-25 | Dry acid-chitosan complexes |
US09/947,248 Abandoned US20030018176A1 (en) | 1999-02-25 | 2001-09-06 | Dry acid-chitosan complexes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/515,051 Expired - Fee Related US6326475B1 (en) | 1999-02-25 | 2000-02-25 | Dry acid-chitosan complexes |
Country Status (10)
Country | Link |
---|---|
US (2) | US6326475B1 (en) |
EP (1) | EP1154800A2 (en) |
JP (1) | JP2003512477A (en) |
KR (1) | KR20010102383A (en) |
CN (1) | CN1196496C (en) |
AU (1) | AU770170B2 (en) |
BR (1) | BR0010205A (en) |
CA (1) | CA2366943A1 (en) |
NZ (1) | NZ513633A (en) |
WO (1) | WO2000050090A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050203058A1 (en) * | 2004-03-11 | 2005-09-15 | Johnson Edwin L. | Compositions of alpha- and beta-chitosan and methods of preparing them |
US20080190861A1 (en) * | 2007-02-14 | 2008-08-14 | Branning Merle L | Composition and method for agglomerating solids in solid-liquid separation processes |
US8168767B2 (en) | 2010-06-18 | 2012-05-01 | Halosource, Inc. | Formulations and methods for solid chitosan-containing blends |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030069206A1 (en) * | 1998-07-10 | 2003-04-10 | Nichols Everett J. | Methods and kits for absorbing fat |
FR2805465B1 (en) * | 2000-02-28 | 2003-02-21 | Medecine Information Formation | NEW PHARMACEUTICAL OR DIETETIC COMPOSITIONS BASED ON MUSHROOMS |
US6797290B2 (en) | 2001-09-17 | 2004-09-28 | Mcneil-Ppc, Inc. | Compositions for appetite control and related methods |
US6749748B1 (en) | 2001-12-28 | 2004-06-15 | Vanson Halosource, Inc. | Methods for reducing the amount of contaminants in water |
ES2209632B1 (en) * | 2002-08-30 | 2005-08-01 | Romildo Holding, N.V. | DIETETIC, SOLUBLE, EFFECTIVE AND FOOD COMPLEMENT. |
JP2004131622A (en) * | 2002-10-11 | 2004-04-30 | Dainichiseika Color & Chem Mfg Co Ltd | Aqueous solution of chitosan, method for producing the same and method for coating article |
KR100506710B1 (en) * | 2003-03-24 | 2005-08-05 | 주식회사 건풍바이오 | Chitosan oligosaccharide ascorbic acid salt having anti-diabetic effect |
US7052722B2 (en) * | 2003-12-01 | 2006-05-30 | Cj Corp. | Composition for weight reduction comprising water-soluble low-molecular weight chitosan and Hibiscus extract |
FR2874925A1 (en) * | 2004-05-25 | 2006-03-10 | Richard Cancel | New chitosan salts soluble at acidic pH, useful for trapping fats to prevent their absorption, also for treating rheumatic and other pain |
FR2874926B1 (en) * | 2004-05-25 | 2007-05-11 | Gerard Sassi | CHITOSAN SALTS FOR INHIBITING FAT ADSORPTION AND METHODS OF PREPARATION THEREOF |
ITMI20050150A1 (en) * | 2005-02-03 | 2006-08-04 | Umberto Cornelli | FOODSTUFFS |
US20060177489A1 (en) * | 2005-02-07 | 2006-08-10 | Massouda Debora F | Attachment of chitosan to surfaces using rehydration process |
KR20080080641A (en) * | 2005-12-16 | 2008-09-04 | 디엔피 캐나다 인코포레이티드 | Chitin Derivatives for Hyperlipidemia |
GB0625813D0 (en) * | 2006-12-22 | 2007-02-07 | Advanced Biopolymers As | Process |
CN101029094B (en) * | 2007-04-12 | 2010-07-28 | 武汉大学 | A kind of preparation method of chitosan hydrochloride |
RU2412713C2 (en) * | 2009-05-14 | 2011-02-27 | Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" | Pharmaceutic composition, biologically active additive and method of reducing fat absorption from food |
CA2764857A1 (en) * | 2009-06-16 | 2010-12-23 | Halosource, Inc. | Formulations and methods for solid chitosan-containing blends |
CN104891629A (en) * | 2010-06-18 | 2015-09-09 | 哈洛资源公司 | Preparation of solid-state blend containing chitosan and method |
RU2535141C1 (en) * | 2013-04-08 | 2014-12-10 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Саратовский Государственный Университет Имени Н.Г. Чернышевского" | Gel composition of wide spectrum of biological action |
CN105085940B (en) * | 2015-09-23 | 2018-08-21 | 山东商业职业技术学院 | The quick dissolution method of chitosan |
CN109593518A (en) * | 2018-12-06 | 2019-04-09 | 古莱特科技股份有限公司 | A kind of solid acid de-plugging system for acidification of oil field de-plugging |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4574150A (en) * | 1985-02-19 | 1986-03-04 | University Of Delaware | Dry free-flowing water-soluble complexes of chitosan |
US5654001A (en) * | 1992-03-24 | 1997-08-05 | Kirin Beer Kabushiki Kaisha | Dietary lipid digestion-absorption inhibitory agents and ingesta |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1500946A (en) * | 1966-08-10 | 1967-11-10 | Process for obtaining poorly water-soluble biodegradable polymer complexes | |
US4964894A (en) * | 1986-03-31 | 1990-10-23 | Freepons Donald E | Plant growth regulators derived from chitin |
US5061792A (en) * | 1989-03-27 | 1991-10-29 | University Of Delaware | Preparation of chitosan salts in aqueous alcoholic media |
US5708152A (en) * | 1992-03-27 | 1998-01-13 | Ciba Specialty Chemicals Corporation | N-substituted chitosan derivatives in a process for their preparation |
FI98512C (en) * | 1995-06-09 | 1997-07-10 | Cultor Oy | Improving crop yield in plants |
US6184037B1 (en) * | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
FR2754824B1 (en) * | 1996-10-23 | 1999-03-05 | Transgene Sa | NEW COMPOSITION CONTAINING CHITOSAN |
US6167652B1 (en) * | 1997-01-23 | 2001-01-02 | Dcv, Inc. | Method for treating cotyledonous plants |
US5726123A (en) * | 1997-02-12 | 1998-03-10 | Dcv Chitin Technologies, L.P. | Method for treating cotyledonous plants |
US6130321A (en) * | 1998-07-10 | 2000-10-10 | Vanson, Inc. | High tap density chitosan, and methods of production |
-
2000
- 2000-02-25 KR KR1020017010818A patent/KR20010102383A/en not_active Ceased
- 2000-02-25 CA CA002366943A patent/CA2366943A1/en not_active Abandoned
- 2000-02-25 AU AU33800/00A patent/AU770170B2/en not_active Ceased
- 2000-02-25 WO PCT/US2000/004922 patent/WO2000050090A2/en not_active Application Discontinuation
- 2000-02-25 EP EP00911995A patent/EP1154800A2/en not_active Withdrawn
- 2000-02-25 US US09/515,051 patent/US6326475B1/en not_active Expired - Fee Related
- 2000-02-25 JP JP2000600700A patent/JP2003512477A/en active Pending
- 2000-02-25 CN CNB008064989A patent/CN1196496C/en not_active Expired - Fee Related
- 2000-02-25 BR BR0010205-9A patent/BR0010205A/en not_active IP Right Cessation
- 2000-02-25 NZ NZ513633A patent/NZ513633A/en unknown
-
2001
- 2001-09-06 US US09/947,248 patent/US20030018176A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4574150A (en) * | 1985-02-19 | 1986-03-04 | University Of Delaware | Dry free-flowing water-soluble complexes of chitosan |
US5654001A (en) * | 1992-03-24 | 1997-08-05 | Kirin Beer Kabushiki Kaisha | Dietary lipid digestion-absorption inhibitory agents and ingesta |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050203058A1 (en) * | 2004-03-11 | 2005-09-15 | Johnson Edwin L. | Compositions of alpha- and beta-chitosan and methods of preparing them |
US20080190861A1 (en) * | 2007-02-14 | 2008-08-14 | Branning Merle L | Composition and method for agglomerating solids in solid-liquid separation processes |
WO2008101000A2 (en) * | 2007-02-14 | 2008-08-21 | Nalco Company | Composition and method for agglomerating solids in solid-liquid separation processes |
WO2008101000A3 (en) * | 2007-02-14 | 2008-10-09 | Nalco Co | Composition and method for agglomerating solids in solid-liquid separation processes |
US8168767B2 (en) | 2010-06-18 | 2012-05-01 | Halosource, Inc. | Formulations and methods for solid chitosan-containing blends |
US8357787B2 (en) | 2010-06-18 | 2013-01-22 | Halosource, Inc. | Formulations and methods for solid chitosan-containing blends |
Also Published As
Publication number | Publication date |
---|---|
NZ513633A (en) | 2003-10-31 |
WO2000050090A3 (en) | 2001-04-05 |
AU770170B2 (en) | 2004-02-12 |
CN1347328A (en) | 2002-05-01 |
WO2000050090A2 (en) | 2000-08-31 |
CN1196496C (en) | 2005-04-13 |
KR20010102383A (en) | 2001-11-15 |
US6326475B1 (en) | 2001-12-04 |
BR0010205A (en) | 2002-02-19 |
JP2003512477A (en) | 2003-04-02 |
AU3380000A (en) | 2000-09-14 |
EP1154800A2 (en) | 2001-11-21 |
CA2366943A1 (en) | 2000-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6326475B1 (en) | Dry acid-chitosan complexes | |
DE69422465T2 (en) | Cation complexed polysaccharides | |
KR101594790B1 (en) | Solid dialysis solvent | |
IE56214B1 (en) | Easily dispersible dietary fiber product and process for producing the same | |
JPH0745521B2 (en) | Antihypertensive agent having antihypertensive effect | |
JPS641442B2 (en) | ||
JPH07501533A (en) | Pharmaceutical compositions based on Ebathyme or its analogues | |
JP2983716B2 (en) | Food composition comprising a water-soluble dietary fiber complex | |
KR100871050B1 (en) | Preparation method of microcapsules containing coenzyme q-ten | |
JP2003518515A (en) | Stabilized cyclodextrin complex | |
US4675312A (en) | Polysaccharide agglomerate and method of preparation | |
EP1408772A2 (en) | Methods of stabilizing fruit-concentrate powders | |
MXPA01008655A (en) | Dry acid-chitosan complexes | |
WO1995002969A1 (en) | A maltodextrin composition | |
CN115569129A (en) | Carbazoline calcium solid preparation and preparation method thereof | |
KR100473445B1 (en) | cholesterol reducer and health food containing chitosan and ε-polylysine | |
JP4178361B2 (en) | Chitosan-containing powder | |
JP3493585B2 (en) | Blood pressure lowering and serum triglyceride lowering agent | |
WO2023161843A1 (en) | Non-hygroscopic water-soluble curing agents in a granular form | |
KR0153484B1 (en) | Manufacturing method of feed additive | |
WO2021222898A1 (en) | Nutritional supplements comprising dietary metal complexes in a matrix of cellulosic materials | |
JPH0153855B2 (en) | ||
JPH02288834A (en) | Paste composition | |
CN107372836A (en) | A kind of sea-buckthorn blueberry goat milk piece and preparation method thereof | |
JPH0269419A (en) | Readily absorbable calcium composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |